Crossmark

Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission

Crossref DOI link: https://doi.org/10.1016/j.gastre.2024.04.033

Published Print: 2024-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Piñero, Gisela

Mañosa, Míriam

Calafat, Margalida

Vayreda, Eva

Cañete, Fiorella

Puig, Maria

Domènech, Eugeni
License Information

Text and Data Mining valid from 2024-06-01

Text and Data Mining valid from 2024-06-01

stm-asf valid from 2024-06-01

stm-asf valid from 2024-06-01

stm-asf valid from 2024-06-01

stm-asf valid from 2024-06-01

stm-asf valid from 2024-06-01
More Information

This article is maintained by: Elsevier

Article Title: Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission

Journal Title: Gastroenterología y Hepatología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastre.2024.04.033

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.gastrohep.2023.09.011

Content Type: article

Copyright: © 2023 Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.